When analyzing clinical trial results—especially in oncology—two numbers are central to understanding a drug’s impact: the hazard ratio (HR) and the p-value. Investors often glance at p-values for a ...
Wu et al 1 conducted an interesting study-level meta-analysis comparing the efficacy of PD-1 antibody plus chemotherapy with chemotherapy alone in patients with PD-L1–expressing esophageal squamous ...
In this Hogan Lovells update, we first provide a brief overview of the purpose and history of the PCHF Draft Guidance, address the key changes to the draft Introduction, and then discuss some of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results